Selected research
Industry Research
Non-opioid Pain Patch Industry Research Report 2026
Market perspective
The global Non-opioid Pain Patch market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Non-opioid Pain Patch is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Non-opioid Pain Patch is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Non-opioid Pain Patch is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Non-opioid Pain Patch include Sanofi, Johnson & Johnson, Qizheng, Novartis, Mylan, Lingrui, Huarun 999, GSK and Teikoku Seiyaku, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Non-opioid Pain Patch market in terms of revenue (US$ million) and, where applicable, sales volume (M Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Non-opioid Pain Patch Market by Company
Sanofi
Johnson & Johnson
Qizheng
Novartis
Mylan
Lingrui
Huarun 999
GSK
Teikoku Seiyaku
Nichiban
Mentholatum
Laboratoires Genevrier
Hisamitsu
Haw Par
Endo
BLUE-EMU
Actavis
Non-opioid Pain Patch Segment by Type
Fentanyl Patches
Counter-Irritant Patches
Lidocaine Patches
Diclofenac Patches
Indomethacin Patches
Others
Non-opioid Pain Patch Segment by Application
OTC
Rx
Non-opioid Pain Patch Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-opioid Pain Patch market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-opioid Pain Patch and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-opioid Pain Patch.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Non-opioid Pain Patch manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Non-opioid Pain Patch by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Non-opioid Pain Patch in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fentanyl Patches
- Counter-Irritant Patches
- Lidocaine Patches
- Diclofenac Patches
- Indomethacin Patches
- Others
Applications
- OTC
- Rx
Companies covered
- Sanofi
- Johnson & Johnson
- Qizheng
- Novartis
- Mylan
- Lingrui
- Huarun 999
- GSK
- Teikoku Seiyaku
- Nichiban
- Mentholatum
- Laboratoires Genevrier
- Hisamitsu
- Haw Par
- Endo
- BLUE-EMU
- Actavis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Non-opioid Pain Patch Market Size (2021-2032)
- 2.2.2 Global Non-opioid Pain Patch Sales (2021-2032)
- 2.2.3 Global Non-opioid Pain Patch Market Average Price (2021-2032)
- 2.3 Non-opioid Pain Patch by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Fentanyl Patches
- 2.3.3 Counter-Irritant Patches
- 2.3.4 Lidocaine Patches
- 2.3.5 Diclofenac Patches
- 2.3.6 Indomethacin Patches
- 2.3.7 Others
- 2.4 Non-opioid Pain Patch by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 OTC
- 2.4.3 Rx
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Non-opioid Pain Patch Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Non-opioid Pain Patch Sales (M Pcs) of Manufacturers (2021-2026)
- 3.3 Global Non-opioid Pain Patch Revenue of Manufacturers (2021-2026)
- 3.4 Global Non-opioid Pain Patch Average Price by Manufacturers (2021-2026)
- 3.5 Global Non-opioid Pain Patch Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Non-opioid Pain Patch, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Non-opioid Pain Patch, Product Type & Application
- 3.8 Global Manufacturers of Non-opioid Pain Patch, Established Date
- 3.9 Global Non-opioid Pain Patch Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Non-opioid Pain Patch Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Non-opioid Pain Patch Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Qizheng
- 4.3.1 Qizheng Company Information
- 4.3.2 Qizheng Business Overview
- 4.3.3 Qizheng Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qizheng Non-opioid Pain Patch Product Portfolio
- 4.3.5 Qizheng Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Non-opioid Pain Patch Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Mylan
- 4.5.1 Mylan Company Information
- 4.5.2 Mylan Business Overview
- 4.5.3 Mylan Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Non-opioid Pain Patch Product Portfolio
- 4.5.5 Mylan Recent Developments
- 4.6 Lingrui
- 4.6.1 Lingrui Company Information
- 4.6.2 Lingrui Business Overview
- 4.6.3 Lingrui Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lingrui Non-opioid Pain Patch Product Portfolio
- 4.6.5 Lingrui Recent Developments
- 4.7 Huarun 999
- 4.7.1 Huarun 999 Company Information
- 4.7.2 Huarun 999 Business Overview
- 4.7.3 Huarun 999 Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Huarun 999 Non-opioid Pain Patch Product Portfolio
- 4.7.5 Huarun 999 Recent Developments
- 4.8 GSK
- 4.8.1 GSK Company Information
- 4.8.2 GSK Business Overview
- 4.8.3 GSK Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GSK Non-opioid Pain Patch Product Portfolio
- 4.8.5 GSK Recent Developments
- 4.9 Teikoku Seiyaku
- 4.9.1 Teikoku Seiyaku Company Information
- 4.9.2 Teikoku Seiyaku Business Overview
- 4.9.3 Teikoku Seiyaku Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Teikoku Seiyaku Non-opioid Pain Patch Product Portfolio
- 4.9.5 Teikoku Seiyaku Recent Developments
- 4.10 Nichiban
- 4.10.1 Nichiban Company Information
- 4.10.2 Nichiban Business Overview
- 4.10.3 Nichiban Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Nichiban Non-opioid Pain Patch Product Portfolio
- 4.10.5 Nichiban Recent Developments
- 4.11 Mentholatum
- 4.11.1 Mentholatum Company Information
- 4.11.2 Mentholatum Business Overview
- 4.11.3 Mentholatum Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Mentholatum Non-opioid Pain Patch Product Portfolio
- 4.11.5 Mentholatum Recent Developments
- 4.12 Laboratoires Genevrier
- 4.12.1 Laboratoires Genevrier Company Information
- 4.12.2 Laboratoires Genevrier Business Overview
- 4.12.3 Laboratoires Genevrier Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Laboratoires Genevrier Non-opioid Pain Patch Product Portfolio
- 4.12.5 Laboratoires Genevrier Recent Developments
- 4.13 Hisamitsu
- 4.13.1 Hisamitsu Company Information
- 4.13.2 Hisamitsu Business Overview
- 4.13.3 Hisamitsu Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Hisamitsu Non-opioid Pain Patch Product Portfolio
- 4.13.5 Hisamitsu Recent Developments
- 4.14 Haw Par
- 4.14.1 Haw Par Company Information
- 4.14.2 Haw Par Business Overview
- 4.14.3 Haw Par Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Haw Par Non-opioid Pain Patch Product Portfolio
- 4.14.5 Haw Par Recent Developments
- 4.15 Endo
- 4.15.1 Endo Company Information
- 4.15.2 Endo Business Overview
- 4.15.3 Endo Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Endo Non-opioid Pain Patch Product Portfolio
- 4.15.5 Endo Recent Developments
- 4.16 BLUE-EMU
- 4.16.1 BLUE-EMU Company Information
- 4.16.2 BLUE-EMU Business Overview
- 4.16.3 BLUE-EMU Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 BLUE-EMU Non-opioid Pain Patch Product Portfolio
- 4.16.5 BLUE-EMU Recent Developments
- 4.17 Actavis
- 4.17.1 Actavis Company Information
- 4.17.2 Actavis Business Overview
- 4.17.3 Actavis Non-opioid Pain Patch Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Actavis Non-opioid Pain Patch Product Portfolio
- 4.17.5 Actavis Recent Developments
5 Global Non-opioid Pain Patch Market Scenario by Region
- 5.1 Global Non-opioid Pain Patch Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Non-opioid Pain Patch Sales by Region: 2021-2032
- 5.2.1 Global Non-opioid Pain Patch Sales by Region: 2021-2026
- 5.2.2 Global Non-opioid Pain Patch Sales by Region: 2027-2032
- 5.3 Global Non-opioid Pain Patch Revenue by Region: 2021-2032
- 5.3.1 Global Non-opioid Pain Patch Revenue by Region: 2021-2026
- 5.3.2 Global Non-opioid Pain Patch Revenue by Region: 2027-2032
- 5.4 North America Non-opioid Pain Patch Market Facts & Figures by Country
- 5.4.1 North America Non-opioid Pain Patch Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Non-opioid Pain Patch Sales by Country (2021-2032)
- 5.4.3 North America Non-opioid Pain Patch Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Non-opioid Pain Patch Market Facts & Figures by Country
- 5.5.1 Europe Non-opioid Pain Patch Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Non-opioid Pain Patch Sales by Country (2021-2032)
- 5.5.3 Europe Non-opioid Pain Patch Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Non-opioid Pain Patch Market Facts & Figures by Country
- 5.6.1 Asia Pacific Non-opioid Pain Patch Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Non-opioid Pain Patch Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Non-opioid Pain Patch Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Non-opioid Pain Patch Market Facts & Figures by Country
- 5.7.1 South America Non-opioid Pain Patch Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Non-opioid Pain Patch Sales by Country (2021-2032)
- 5.7.3 South America Non-opioid Pain Patch Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Non-opioid Pain Patch Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Non-opioid Pain Patch Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Non-opioid Pain Patch Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Non-opioid Pain Patch Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Non-opioid Pain Patch Sales by Type (2021-2032)
- 6.1.1 Global Non-opioid Pain Patch Sales by Type (2021-2032) & (M Pcs)
- 6.1.2 Global Non-opioid Pain Patch Sales Market Share by Type (2021-2032)
- 6.2 Global Non-opioid Pain Patch Revenue by Type (2021-2032)
- 6.2.1 Global Non-opioid Pain Patch Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Non-opioid Pain Patch Revenue Market Share by Type (2021-2032)
- 6.3 Global Non-opioid Pain Patch Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Non-opioid Pain Patch Sales by Application (2021-2032)
- 7.1.1 Global Non-opioid Pain Patch Sales by Application (2021-2032) & (M Pcs)
- 7.1.2 Global Non-opioid Pain Patch Sales Market Share by Application (2021-2032)
- 7.2 Global Non-opioid Pain Patch Revenue by Application (2021-2032)
- 7.2.1 Global Non-opioid Pain Patch Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Non-opioid Pain Patch Revenue Market Share by Application (2021-2032)
- 7.3 Global Non-opioid Pain Patch Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Non-opioid Pain Patch Value Chain Analysis
- 8.1.1 Non-opioid Pain Patch Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Non-opioid Pain Patch Production Mode & Process
- 8.2 Non-opioid Pain Patch Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Non-opioid Pain Patch Distributors
- 8.2.3 Non-opioid Pain Patch Customers
9 Global Non-opioid Pain Patch Analyzing Market Dynamics
- 9.1 Non-opioid Pain Patch Industry Trends
- 9.2 Non-opioid Pain Patch Industry Drivers
- 9.3 Non-opioid Pain Patch Industry Opportunities and Challenges
- 9.4 Non-opioid Pain Patch Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst